These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 33820908)

  • 1. Diffuse large B-cell lymphoma: new targets and novel therapies.
    Cheson BD; Nowakowski G; Salles G
    Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
    Walji M; Assouline S
    Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Harris LJ; Patel K; Martin M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
    Amaya ML; Jimeno A; Kamdar M
    Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
    Choi Y; Diefenbach CS
    Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
    Di M; Huntington SF; Olszewski AJ
    Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
    Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.
    Takakuwa T; Okayama Y; Nakamae H; Kuno M; Makuuchi Y; Harada N; Okamura H; Nishimoto M; Nakashima Y; Koh H; Hino M
    Ann Hematol; 2022 Jul; 101(7):1609-1610. PubMed ID: 35218398
    [No Abstract]   [Full Text] [Related]  

  • 14. How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure.
    Logue JM; Chavez JC
    Curr Treat Options Oncol; 2021 Oct; 22(12):112. PubMed ID: 34697650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
    Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
    Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
    [No Abstract]   [Full Text] [Related]  

  • 16. Economic evaluation of polatuzumab-bendamustine-rituximab
    Calamia M; McBride A; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma.
    Camus V; Tilly H
    Future Oncol; 2021 Jan; 17(2):127-135. PubMed ID: 32954807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
    Tarantelli C; Bertoni F
    Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
    Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
    Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.